Cite
FRI350 - Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod.
MLA
Chen, Diana, et al. “FRI350 - Potential Biomarkers of Response in Chronic Hepatitis B Patients Who Achieved HBeAg Loss upon Treatment with Toll-like Receptor 8 (TLR8) Agonist Selgantolimod.” Journal of Hepatology, vol. 73, Aug. 2020, pp. S571–72. EBSCOhost, https://doi.org/10.1016/S0168-8278(20)31616-0.
APA
Chen, D., Kim, S., Brooks, A., Zhang, L., Podlaha, O., Yang, J., Gaggar, A., Dunbar, P. R., & Wallin, J. (2020). FRI350 - Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod. Journal of Hepatology, 73, S571–S572. https://doi.org/10.1016/S0168-8278(20)31616-0
Chicago
Chen, Diana, Sam Kim, Anna Brooks, Liao Zhang, Ondrej Podlaha, Jenny Yang, Anuj Gaggar, P. Rod Dunbar, and Jeffrey Wallin. 2020. “FRI350 - Potential Biomarkers of Response in Chronic Hepatitis B Patients Who Achieved HBeAg Loss upon Treatment with Toll-like Receptor 8 (TLR8) Agonist Selgantolimod.” Journal of Hepatology 73 (August): S571–72. doi:10.1016/S0168-8278(20)31616-0.